Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;59(6):3598-601.
doi: 10.1128/AAC.04056-14. Epub 2015 Mar 23.

Evaluation of α,β-unsaturated ketones as antileishmanial agents

Affiliations

Evaluation of α,β-unsaturated ketones as antileishmanial agents

Miguel A Vasquez et al. Antimicrob Agents Chemother. 2015.

Abstract

In this study, we assessed the antileishmanial activity of 126 α,β-unsaturated ketones. The compounds NC901, NC884, and NC2459 showed high leishmanicidal activity for both the extracellular (50% effective concentration [EC50], 456 nM, 1,122 nM, and 20 nM, respectively) and intracellular (EC50, 1,870 nM, 937 nM, and 625 nM, respectively) forms of Leishmania major propagated in macrophages, with little or no toxicity to mammalian cells. Bioluminescent imaging of parasite replication showed that all three compounds reduced the parasite burden in the murine model, with no apparent toxicity.

PubMed Disclaimer

Figures

FIG 1
FIG 1
In vivo activity of compounds NC901, NC884, and NC2459 in the murine model of CL. (A and B) Footpad size of BALB/c mice infected with 105 and 106 L. major metacyclic promastigotes, respectively. The Rx1 line refers to the time period in which treatment was administered daily, and the Rx2 line indicates that the daily dosage of NC2459 was doubled for that time period. (C) Luminescence of BALB/c mice footpads at 46 days postinfection with 105 metacyclic promastigotes. *, P < 0.05. (D) Luminescence of BALB/c mice footpads at 29 days postinfection with 106 metacyclic promastigotes. C, group treated with vehicle control; CD, group treated with amphotericin B. A statistical analysis of the net intensity (luminescence) of both the 105 and 106 experiments was carried out using the two-sided unpaired t test. *, P ≤ 0.05; **, P ≤ 0.01.

References

    1. Das S, Das U, Varela-Ramirez A, Lema C, Aguilera RJ, Balzarini J, De Clercq E, Dimmock SG, Gorecki DK, Dimmock JR. 2011. Bis[3,5-bis(benzylidene)-4-oxo-1-piperidinyl]amides: a novel class of potent cytotoxins. ChemMedChem 6:1892–1899. doi:10.1002/cmdc.201100199. - DOI - PMC - PubMed
    1. Alvar J, Velez ID, Bern C, Herrero M, Desieux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team. 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7:e35671. doi:10.1371/journal.pone.0035671. - DOI - PMC - PubMed
    1. Haldar AK, Sen P, Roy S. 2011. Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int 2011:571242. doi:10.4601/2011/571242. - DOI - PMC - PubMed
    1. Croft SL, Barrett MP, Urbina JA. 2005. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 21:508–512. doi:10.1016/j.pt.2005.08.026. - DOI - PubMed
    1. Desjeux P. 2004. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27:305–318. doi:10.1016/j.cimid.2004.03.004. - DOI - PubMed

Publication types

LinkOut - more resources